- Influenza
- Vaccine Recommendations
Are any of the available influenza vaccines recommended over others?
For people age 6 months through 64 years, CDC recommends any available age-appropriate influenza vaccine product.
For adults age 65 years and older, three influenza vaccines are preferentially recommended: Fluzone High-Dose (HD-IIV, Sanofi), Flublok recombinant (RIV, Sanofi), and Fluad adjuvanted (aIIV, CSL Seqirus). In June 2022, ACIP concluded that these three vaccines are potentially more effective than standard dose, unadjuvanted flu vaccines. However, if none of the three products are available, people age 65 years and older should get any other age-appropriate influenza vaccine.
Review the full explanation for the ACIP decision to prefer these products in this age group in the 2022 ACIP recommendations for influenza vaccination: www.cdc.gov/mmwr/volumes/71/rr/pdfs/rr7101a1-H.pdf.
ACIP recommends that solid organ transplant recipients (SOTRs) age 18 years through 64 years have the option of receiving HD-IIV or aIIV, both of which are licensed for people age 65 years or older. However, HD-IIV and aIIV are not preferentially recommended over age-appropriate influenza vaccine products for SOTRs.